
|Videos|July 9, 2020
Ground-Breaking Data from the Phase III ADAURA Trial
Author(s)Targeted Oncology
A primary researcher on the Phase III ADAURA trial provides an overview of the ground-breaking data for managing patients with EGFR-positive NSCLC (non–small cell lung cancer).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Savolitinib Plus Osimertinib Improves PFS, OS in MET-Driven NSCLC
2
FDA Grants Type C Meeting for OST-HER2 OS Data in Osteosarcoma
3
VA Study Finds Potential OS Benefit for Enzalutamide in Older mCSPC Patients
4
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
5





























